Important Information for Maravai LifeSciences Holdings, Inc. Investors: Securities Class Action Lawsuit Filed
On March 12, 2025, Cohen Milstein Sellers & Toll PLLC announced the filing of a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI) on behalf of investors who purchased or otherwise acquired Maravai shares between August 7, 2024, and February 24, 2025 (the “Class Period”).
Background
Maravai LifeSciences Holdings, Inc. is a leading provider of specialty ingredients and contract development and manufacturing services to the pharmaceutical and biotechnology industries. The Company’s products and services are used in a wide range of applications, including the development and manufacture of active pharmaceutical ingredients (APIs), intermediates, and advanced intermediates.
Allegations
The complaint alleges that Maravai and certain of its executives made false and misleading statements and failed to disclose material information during the Class Period, violating the Securities Exchange Act of 1934. Specifically, the complaint alleges that Maravai failed to disclose that:
- The Company’s financial statements for the fiscal years ended December 31, 2022, and 2023 contained material misstatements and omissions;
- Maravai’s revenue growth was driven in part by illegal and improper practices;
- The Company’s internal controls over financial reporting were inadequate;
- Maravai’s financial results for the quarters ending September 30, 2024, and December 31, 2024, would be materially impacted by correcting these issues.
Impact on Individual Investors
If you purchased or otherwise acquired Maravai shares during the Class Period, you may be entitled to recover your losses through this securities class action. The securities class action process allows investors to recover their losses through a single lawsuit, rather than pursuing individual claims. The lawsuit seeks to hold Maravai and its executives accountable for their alleged misconduct and to recover damages for investors.
Impact on the World
The securities class action lawsuit against Maravai LifeSciences Holdings, Inc. is an important step in ensuring transparency and accountability in the financial markets. By holding companies and their executives accountable for misrepresentations and omissions, securities class actions help protect investors and maintain confidence in the integrity of the markets. This, in turn, helps to promote economic growth and stability.
Conclusion
If you purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. shares between August 7, 2024, and February 24, 2025, and believe that you may have lost money as a result of the Company’s alleged securities law violations, you are encouraged to contact Cohen Milstein Sellers & Toll PLLC to discuss your legal options. The securities class action process provides an opportunity for investors to recover their losses and hold companies accountable for their actions. By taking action, you can help promote transparency and integrity in the financial markets and protect your investments.
For more information, please contact Cohen Milstein representative or reach out to Partner Molly Bowen at [email protected].
